Private Advisor Group LLC Buys New Position in Charles River Laboratories Intl. Inc (CRL)

Private Advisor Group LLC bought a new position in Charles River Laboratories Intl. Inc (NYSE:CRL) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 32,742 shares of the medical research company’s stock, valued at approximately $769,000. Private Advisor Group LLC owned approximately 0.07% of Charles River Laboratories Intl. at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of CRL. Bessemer Group Inc. boosted its position in shares of Charles River Laboratories Intl. by 2.3% in the fourth quarter. Bessemer Group Inc. now owns 1,933 shares of the medical research company’s stock worth $147,000 after buying an additional 43 shares in the last quarter. Cornercap Investment Counsel Inc. boosted its position in shares of Charles River Laboratories Intl. by 1.0% in the fourth quarter. Cornercap Investment Counsel Inc. now owns 7,430 shares of the medical research company’s stock worth $566,000 after buying an additional 70 shares in the last quarter. Cardinal Capital Management boosted its position in shares of Charles River Laboratories Intl. by 1.1% in the first quarter. Cardinal Capital Management now owns 7,035 shares of the medical research company’s stock worth $633,000 after buying an additional 76 shares in the last quarter. State Treasurer State of Michigan boosted its position in shares of Charles River Laboratories Intl. by 0.5% in the first quarter. State Treasurer State of Michigan now owns 19,200 shares of the medical research company’s stock worth $1,727,000 after buying an additional 100 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV boosted its position in shares of Charles River Laboratories Intl. by 5.0% in the first quarter. Massmutual Trust Co. FSB ADV now owns 2,739 shares of the medical research company’s stock worth $246,000 after buying an additional 130 shares in the last quarter. Institutional investors own 95.32% of the company’s stock.

Institutional Ownership by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Shares of Charles River Laboratories Intl. Inc (NYSE:CRL) traded up 1.04% during trading on Thursday, reaching $89.40. The company’s stock had a trading volume of 309,450 shares. Charles River Laboratories Intl. Inc has a one year low of $67.20 and a one year high of $92.61. The stock’s 50 day moving average is $89.03 and its 200 day moving average is $82.35. The firm has a market cap of $4.26 billion, a P/E ratio of 26.16 and a beta of 0.99.

Charles River Laboratories Intl. (NYSE:CRL) last announced its quarterly earnings results on Wednesday, May 10th. The medical research company reported $1.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.14 by $0.15. The firm had revenue of $445.80 million for the quarter, compared to the consensus estimate of $437.04 million. Charles River Laboratories Intl. had a return on equity of 25.75% and a net margin of 9.05%. The company’s quarterly revenue was up 25.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.98 earnings per share. On average, equities analysts forecast that Charles River Laboratories Intl. Inc will post $5.10 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://sportsperspectives.com/2017/05/19/private-advisor-group-llc-buys-new-position-in-charles-river-laboratories-intl-inc-crl.html.

A number of brokerages recently issued reports on CRL. Jefferies Group LLC reiterated a “buy” rating and issued a $106.00 target price on shares of Charles River Laboratories Intl. in a report on Friday, April 21st. Barclays PLC set a $90.00 target price on Charles River Laboratories Intl. and gave the stock a “hold” rating in a report on Saturday, May 13th. Finally, Citigroup Inc reiterated a “neutral” rating and issued a $104.00 target price (up from $90.00) on shares of Charles River Laboratories Intl. in a report on Thursday, May 11th. Six research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $88.06.

In other news, Chairman James C. Foster sold 9,717 shares of the company’s stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $87.64, for a total transaction of $851,597.88. Following the transaction, the chairman now directly owns 388,294 shares of the company’s stock, valued at $34,030,086.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider William D. Barbo sold 1,900 shares of the company’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $87.90, for a total value of $167,010.00. Following the transaction, the insider now directly owns 22,224 shares in the company, valued at $1,953,489.60. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 73,112 shares of company stock worth $6,484,138. Corporate insiders own 2.30% of the company’s stock.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

5 Day Chart for NYSE:CRL

Receive News & Ratings for Charles River Laboratories Intl. Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply